ArticleJournal of immunology (Baltimore, Md. : 1950)2026
Different clinical forms of Plasmodium vivax infection result in unique T cell epitope-specific immune responses.
Article in Journal of immunology (Baltimore, Md. : 1950), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Malaria remains a significant public health concern despite a steady decline in symptomatic cases. In Brazil, endemic regions are primarily concentrated in the Amazon region, where most cases are attributed to Plasmodium vivax. Although malaria does not confer long-term sterilizing immunity, clinical immunity is achieved, leading to asymptomatic (ASY) infections. Assessing cellular immunity against P. vivax is challenging due to the lack of well-defined antigens. Hence, we developed a library of 310 P. vivax peptides (MPv310) to evaluate antigen-specific responses of CD4+ T cells and their memory subpopulations. The specific cytokine response, IFN-γ and TNF, and upregulation of activation markers, CD69 and CD154, were assessed in P. vivax-infected individuals, including symptomatic before treatment (SY-I) patients, symptomatic after treatment (SY-T) patients, ASY individuals, and uninfected individuals. CD4+ T cells were stimulated with peptides and analyzed by flow cytometry or ELISpot. MPv310 stimulation led to increased frequencies of CD154+ and CD69+CD154+ cells in symptomatic before treatment and SY-T patients and IFN-γ+TNF+ cells in SY-T patients. Cytokine response was also associated with ASY status, with higher frequencies of IFN-γ+TNF+ among CD4+ T cells and of IFN-γ+ in the effector memory subset. Distinct antigen-specific activation patterns were also observed among symptomatic and ASY individuals when the peptide pool was divided into smaller pools representing specific antigens. This study reveals that MPv310 and different sets of minipools stimulate CD4+ T cells in symptomatic and ASY infections, having potential to be used as a new tool to assess immune mechanisms associated with different clinical presentations of the disease and protection against malaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.